Stress was characterized by Hans Selye, in 1936, as the "stereotyped biological response to any demand." Corticotrophin-releasing factor (CRF) and its related peptides urocortins (Ucns 1,2,3) are the mediators of stress. They are present both in the central nervous system and in the gastrointestinal (GI) tract where they exert their biological actions on target cells through activation of two receptors, CRF1 and CRF2. Stress is able to modulate numerous functions of the GI tract such as motility, secretion, permeability, sensitivity, and microbiota. Classically, stress delays gastric emptying while stimulating colonic transit and secretion, increases intestinal permeability and visceral sensitivity, and modifi es intestinal microbiota. Through these various effects at the level of the GI tract, stress is involved in the pathophysiology of irritable bowel syndrome (IBS), a functional digestive disorder, as well as infl ammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis. Targeting these CRF1/CRF2 signaling pathways by selective antagonists/agonists should be of clinical interest in the domain of IBS and IBD.
Stress-Defi nitionIn 1936, Hans Selye defi ned the concept of stress as the "stereotyped biological response to any demand" [ 168 ] and elaborated the concept of the general adaptation syndrome. Later, the hypothalamic factor named corticotrophin-releasing factor (CRF) which stimulates ACTH release by the rat pituitary was discovered [ 77 ], positioning the hypothalamic-pituitary adrenal (HPA) axis as a key element in this concept. In 1981, Vale and his group [ 196 ] identifi ed the 41-aa peptide CRF characterized